Jeppson Wealth Management LLC Buys 4,411 Shares of Pfizer Inc. $PFE

Jeppson Wealth Management LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.3% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 37,526 shares of the biopharmaceutical company’s stock after acquiring an additional 4,411 shares during the period. Jeppson Wealth Management LLC’s holdings in Pfizer were worth $910,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Capital Advisory Group Advisory Services LLC increased its position in shares of Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares during the last quarter. Trust Co of the South increased its position in shares of Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares during the last quarter. Charter Oak Capital Management LLC increased its position in shares of Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 444 shares during the last quarter. Ballentine Partners LLC increased its position in shares of Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the last quarter. Finally, Members Trust Co increased its position in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 467 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.3%

PFE stock opened at $24.07 on Thursday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $136.82 billion, a price-to-earnings ratio of 12.80, a PEG ratio of 0.85 and a beta of 0.55. The business has a 50 day simple moving average of $24.59 and a two-hundred day simple moving average of $24.18.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.